Census of all Suboxone lawsuits will help the parties determine which tooth decay claims could be used as representative samples in early bellwether trials.
Suboxone tooth decay data will be produced as the parties work to exchange information needed to select a representative group of lawsuits for early bellwether trials.
Lawyers will meet with the MDL judge presiding over all Suboxone tooth decay lawsuits on October 4 and 5, to finalize information needed to select the first cases for bellwether discovery and trials.
A report will be submitted next week about the status of investigations into thousands of Suboxone dental injury lawsuits filed on a bundled complaint.
Lawyers are expected to discuss how to select a representative group of claims involving Suboxone dental injuries during a meeting with the Court on October 5.
In response to a motion to dismiss filed by Indivior, plaintiffs indicate that the drug maker knew about the risk of tooth decay problems from Suboxone long before the FDA required an update to the label warning.
Suboxone manufacturer attempts to argue that failure to warn and design defect claims over tooth decay risks should be preempted by federal law.
Lawyers have been ordered to submit proposals for exchanging information that will guide the selection of representative Suboxone dental claims for bellwether discovery and test trials.
A tolling agreement for Suboxone tooth decay lawsuits will provide additional time for potential claims to be investigated before they are placed on the MDL docket, where more than 10,000 individual lawsuits may soon have to be filed
As a result of the order, lawsuits over Suboxone tooth decay will move forward with a standard discovery process, preparing a small group of representative cases for early test trials in the federal MDL.
